drugset
drugset / Trial / NCT07509008

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

NCT07509008 ↗

Phase 1/2 Not yet recruiting 10 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to study the recommended dose of TROP2 CAR/IL-15 TGFBR2 KO NK cells that can be given intraperitoneally (infused directly into the stomach area) to participants with adenocarcinoma of the stomach that has spread to the peritoneum. The safety and effectiveness of this treatment will also be studied.

Timeline

Start
2026-09-01
Primary completion
2028-07-01
Completion
2030-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject TGFBR2 KO CAR27/IL-15 NK cells Cell therapy — Other
Background Cyclophosphamide Other / unclassified — Intravenous
Background Fludarabine Small molecule — Intravenous
Background Rimiducid Other / unclassified — Intravenous

Indications

gastric adenocarcinoma